Home » Newsletters » BioWorld Science

BioWorld Science

Nov. 30, 2012

View Archived Issues

Evotec and Probiodrug enter development collaboration for novel enzyme target

Kythera's ATX-101 is safe in interim study results

Proof-of-concept results reported for BAY-94-8862

Starpharma reports data from two phase III VivaGel studies

PAX2 identified in CNS hemangioblastomas

Shionogi & Co. presents new NPY5 receptor antagonists

RVX-297 reduces clinical signs of disease in a rat model of rheumatoid arthritis

First-in-human study of AT-406 described

Novel PDE10 inhibitors disclosed by Mochida Pharmaceutical

Exelixis prepares new iPFK2 inhibitors for cancer

Curis licenses GDC-0917 from Genentech

Shionogi & Co. presents new BACE1 inhibitors

Merck & Co. updates on ridaforolimus MAA

Japan Tobacco designs novel RORgamma antagonists

Protalex treats first patient phase Ib PRTX-100 trial

MM-938 significantly reduces tumor growth rates in glioblastoma mouse models

Novel protein kinase inhibitors patented by Abbott Laboratories

Nordic Pharma gains marketing rights for Veregen in certain countries

Preclinical and phase I data presented for AP-26113

Bayer and Leiden University to coordinate drug discovery consortium

Tekmira acquires license to RNAi technology

Phase II trial of pancreas cancer vaccines completes enrollment

Immunovative Therapies receives clearance for phase II/III trial in Thailand

Novel mouse model of NSF developed at Thomas Jefferson University

FDA approves Cometriq, EMA accepts MAA

Enrollment complete in pivotal U.S. phase III trial of NX-1207

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 23, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Dec. 23, 2025.
HIV research is close to a cure but far from ending the pandemic
BioWorld
Advances in antiretroviral therapy (ART) now allow people living with HIV to lead normal lives with undetectable and nontransmissible levels of the virus in their...
Researchers discover how glioblastoma tumors dodge chemotherapy
BioWorld MedTech
Researchers at the University of Sydney have uncovered a mechanism that may explain why glioblastoma returns after treatment, and the world-first discovery offers...
ABS-1230 controls seizures in KCNT1-driven severe epilepsy
BioWorld Science
Mutations in the KCNT1 gene produce gain-of-function effects that lead to overactivation of the potassium channel and consequent disruption of normal neuronal...